WST (STOCKS)
West Pharmaceutical Services, Inc.
$248.250000
+4.690000 (+1.93%)
Prev close: $243.560000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Eric Mark Green
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $17,716.06M
- Employees
- 10,600
- P/E (TTM)
- 36.46
- P/B (TTM)
- 5.80
- Dividend Yield
- 34.94%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
12
Buy
5
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$1.96 | $1.70 | +0.2616 | +15.40% |
|
Jun 2025 (Q2)
|
$1.84 | $1.52 | +0.3153 | +20.68% |
|
Mar 2025 (Q1)
|
$1.45 | $1.25 | +0.2043 | +16.40% |
|
Dec 2024 (Q4)
|
$1.82 | $1.74 | +0.0831 | +4.78% |
Financial Statements
| Revenues | $3.02B |
| Benefits Costs and Expenses | $2.41B |
| Cost Of Revenue | $1.94B |
| Costs And Expenses | $2.41B |
| Gross Profit | $1.07B |
| Operating Expenses | $485.80M |
| Selling, General, and Administrative Expenses | $371.90M |
| Research and Development | $71.00M |
| Other Operating Expenses | $42.90M |
| Operating Income/Loss | $587.90M |
| Income/Loss Before Equity Method Investments | $604.30M |
| Income/Loss From Continuing Operations After Tax | $479.20M |
| Income/Loss From Continuing Operations Before Tax | $604.30M |
| Income/Loss From Equity Method Investments | $12.50M |
| Income Tax Expense/Benefit | $125.10M |
| Net Income/Loss | $491.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $491.70M |
| Net Income/Loss Available To Common Stockholders, Basic | $491.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $6.79 |
| Diluted Earnings Per Share | $6.75 |
| Basic Average Shares | 144,400,000 |
| Diluted Average Shares | 145,300,000 |
| Assets | $4.11B |
| Current Assets | $1.82B |
| Inventory | $438.00M |
| Other Current Assets | $1.39B |
| Noncurrent Assets | $2.28B |
| Fixed Assets | $1.74B |
| Intangible Assets | $8.90M |
| Other Non-current Assets | $533.00M |
| Liabilities | $1.05B |
| Current Liabilities | $635.40M |
| Accounts Payable | $255.80M |
| Other Current Liabilities | $379.60M |
| Noncurrent Liabilities | $418.90M |
| Long-term Debt | $202.70M |
| Other Non-current Liabilities | $216.20M |
| Equity | $3.05B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.05B |
| Liabilities And Equity | $4.11B |
| Net Cash Flow From Operating Activities | $693.80M |
| Net Cash Flow From Operating Activities, Continuing | $693.80M |
| Net Cash Flow From Investing Activities | -$314.60M |
| Net Cash Flow From Investing Activities, Continuing | -$314.60M |
| Net Cash Flow From Financing Activities | -$242.30M |
| Net Cash Flow From Financing Activities, Continuing | -$242.30M |
| Exchange Gains/Losses | $700.00K |
| Net Cash Flow | $137.60M |
| Net Cash Flow, Continuing | $136.90M |
| Comprehensive Income/Loss | $356.30M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $525.70M |
| Other Comprehensive Income/Loss | $525.70M |
| Other Comprehensive Income/Loss Attributable To Parent | $34.00M |